Abstract: The present disclosure provides methods of treating a disease or delivering a therapeutic agent to a mammal comprising administering to the mammal's cisterna magna and/or ventricle an rAAV particle containing a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of AAV inverted terminal repeats in a manner such that cells with access to the cerebrospinal fluid (CSF) express the therapeutic agent and in certain embodiments secretes the therapeutic agent into the CSF for distribution to the brain.

Abstract: The present invention relates to plasmid-based miR inhibitory systems (PMIS), miR inhibitors and methods of use of these systems and inhibitors.

Abstract: In certain embodiments, the present invention provides a method of increasing liquid pH on airway surface of a tissue in a patient in need thereof comprising administering an effective amount of a therapeutic composition comprising tromethamine to the patient.

Abstract: The various embodiments disclosed here relate to systems, methods, and devices for monitoring bladder health. Certain implementations are directed to patients who require daily catheterization. The various embodiments have at least one tube coupled to a catheter, a pressure sensor, a pump, and a processor. Certain embodiments include a digital device with a software application capable of displaying the monitored readings.

Abstract: In certain embodiments, the present invention provides a method to identify driver mutations in a tumor and its cancer cell subpopulations. The method of the present invention is used to design treatment strategies for cancer patients.

Abstract: Immunogenic compositions and methods of using them include a biodegradable or bioerodible polyanhydride nanoparticle comprising 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and 1,6-bis(p-carboxyphenoxy)hexane (CPH) copolymers, an immunogenic protein of an Influenza Virus and an adjuvant entrapped within an interior of the nanoparticle, and an excipient. The immunogenic composition may be administered to a subject to confer both local and systemic immunity to the Influenza Virus.

Abstract: The disclosure provides compositions and methods involving viral RNA segments for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation. In addition, modification of the viral sequences responsible for modulating immune response provides for improved vaccine formulations.

Abstract: The disclosed apparatus, systems and methods relate to a framelet-based iterative algorithm for polychromatic CT which can reconstruct two components using a single scan. The algorithm can have various steps including a scaled-gradient descent step of constant or variant step sizes; a non-negativity step; a soft thresholding step; and a color reconstruction step.

Abstract: The present disclosure provides targeting peptides and vectors containing a sequence that encodes targetting peptides that deliver agents, to the eye. The present inventors have discovered peptides that function to target agents, such as viral vectors, to ocular cells. The present disclosure describes a method to utilize these novel peptides to direct, for example, viral capsids to the cell type of interest. In this instance, ocular cells (such as retinal cells) are targeted by the identified peptides. Vectors harboring capsid proteins modified to include such peptides can be used to provide therapeutic agents to the eye.

Abstract: The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula (I): T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula (I).

Abstract: A system and method for stabilizing a spine of an animal subject involving a transverse rod installation instrument assembly for inserting a transverse rod on the spine of a subject percutaneously comprising: a first rod clamp extender mounted on a ipsilateral rod clamp and a second rod clamp extender mounted on a contralateral rod clamp wherein the ipsilateral rod clamp and the contralateral rod clamp are secured to a vertebra at the ipsilateral and contralateral pedicle; and a pivoting installation instrument pivotably mounted to the first rod clamp extender and the second rod clamp extender to pass a transverse rod percutaneously through a head portion of the ipsilateral side rod clamp and to the head portion of the contralateral rod clamp after passing through a spinous process of the vertebra through pivot axis “A” such that the transverse rod is secured at the head portion of the ipsilateral rod clamp and the head portion of the contralateral rod clamp.

Abstract: An adjustable cranioplasty plate assembly is provided for use following a craniectomy. The assembly includes a ring which is attached to the skull around the skull opening and a plate adjustably mounted to the ring. The plate is moveable between a raised position spaced above the ring and a lower position substantially flush with the ring. The plurality of extendable and retractable struts extends between the ring and the plate to provide the plate adjustability. The plurality of stay cables extending between the ring and the plate provide lateral stability in the raised position. The assembly replaces the native bone and eliminates the need for subsequent cranioplasty surgery. In one embodiment, the plate includes a rigid central portion, three rigid mounting tabs, and a plurality of malleable tapered perimeter petals which provide a smooth interface between the plate and the skull of the patient.

Abstract: The present disclosure provides CAPN5 substrates and CAPN5 inhibitors, nucleic acids encoding CAPN5 substrates or CAPN5 inhibitors, methods to deliver CAPN5 substrate or CAPN5 inhibitor agents to the eye, and methods of identifying inhibitors of CAPN5.

Abstract: A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and/or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and/or treating a disease, disorder, and/or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.

Abstract: Disclosed are methods and systems for analyzing data. An example method can comprise receiving volume data representative of an object. A first graph can be generated based on the volume data. The first graph can comprise nodes arranged in a Euclidean space. A deformation field can be determined based on the volume data. The deformation field can be applied to the first graph to form a second graph. The second graph can comprise nodes arranged in a non-Euclidean space. The second graph can be segmented.

Abstract: In certain embodiments, the present invention provides a musclin peptide and methods of increasing muscle growth, performance, resistance to injury and/or preventing or reducing muscle atrophy and improving overall skeletal muscle, metabolic and cardiac health in an animal in need thereof by administering a musclin peptide.

Abstract: In certain embodiments, the present invention provides the use of microRNA (miR)-200a to inhibit ossification and bone formation.

Abstract: In some embodiments, the present disclosure provides an apparatus and methods for selectively lysing cells from a cell suspension including disassociating a population of cells from a tissue sample, the population of cells including a population of one or more viable cells and a population of one or more dead and dying cells, exposing the population of cells to at least one pulse of fluid shear stress having a force along a conduit wall of from about 500 dyn/cm2 to about 2500 dyn/cm2 to substantially lyse the population of one or more dead or dying cells, leaving the population of one or more viable cells substantially intact, and collecting the population of one or more viable cells.

Abstract: The present disclosure provides methods of treating a disease or delivering a therapeutic agent to a mammal comprising administering to the mammal's cisterna magna and/or ventricle an rAAV particle containing a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of AAV inverted terminal repeats in a manner such that cells with access to the cerebrospinal fluid (CSF) express the therapeutic agent and in certain embodiments secretes the therapeutic agent into the CSF for distribution to the brain.

Abstract: A solar control film having a frequency selective surface is provided. The frequency selective surface includes two layers. The first layer and the second layer which includes a metal surface. The frequency selective surface provides at least one UV absorptive material that permits substantial transmission of visible light. Products comprising the solar control film having the frequency selective surface are provided.